| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 19 | 2025 | 330 | 5.030 |
Why?
|
| Septal Occluder Device | 16 | 2025 | 56 | 3.410 |
Why?
|
| Heart-Assist Devices | 11 | 2018 | 898 | 2.520 |
Why?
|
| Shock, Cardiogenic | 6 | 2024 | 172 | 2.290 |
Why?
|
| Heart Arrest | 14 | 2024 | 312 | 2.080 |
Why?
|
| Foramen Ovale, Patent | 3 | 2025 | 24 | 1.960 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2017 | 143 | 1.910 |
Why?
|
| Myocardial Infarction | 12 | 2024 | 429 | 1.800 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2024 | 248 | 1.780 |
Why?
|
| Ventricular Fibrillation | 10 | 2016 | 70 | 1.740 |
Why?
|
| Myocardial Ischemia | 8 | 2024 | 167 | 1.670 |
Why?
|
| Echocardiography, Transesophageal | 14 | 2024 | 362 | 1.610 |
Why?
|
| Heart Valve Prosthesis Implantation | 7 | 2023 | 197 | 1.580 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 662 | 1.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2024 | 217 | 1.510 |
Why?
|
| Absorbable Implants | 4 | 2021 | 37 | 1.430 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2025 | 180 | 1.420 |
Why?
|
| Aortic Valve | 5 | 2023 | 273 | 1.420 |
Why?
|
| Aortic Valve Stenosis | 6 | 2023 | 166 | 1.390 |
Why?
|
| Coronary Vessels | 8 | 2024 | 201 | 1.390 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2019 | 70 | 1.370 |
Why?
|
| Coronary Angiography | 17 | 2024 | 261 | 1.350 |
Why?
|
| Popliteal Artery | 3 | 2021 | 30 | 1.320 |
Why?
|
| Peripheral Arterial Disease | 3 | 2021 | 102 | 1.310 |
Why?
|
| Treatment Outcome | 41 | 2025 | 9175 | 1.280 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 98 | 1.230 |
Why?
|
| Heart Failure | 9 | 2021 | 1422 | 1.200 |
Why?
|
| Ischemia | 2 | 2020 | 256 | 1.110 |
Why?
|
| Coronary Artery Disease | 8 | 2024 | 394 | 1.070 |
Why?
|
| Percutaneous Coronary Intervention | 7 | 2020 | 76 | 1.050 |
Why?
|
| Thrombosis | 4 | 2025 | 326 | 1.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 9 | 2012 | 67 | 1.010 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2024 | 514 | 0.990 |
Why?
|
| Prosthesis Design | 11 | 2024 | 310 | 0.980 |
Why?
|
| Endothelin-1 | 3 | 2011 | 41 | 0.920 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2025 | 73 | 0.910 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1096 | 0.890 |
Why?
|
| Male | 64 | 2025 | 45863 | 0.890 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2020 | 103 | 0.870 |
Why?
|
| Ultrasonography, Interventional | 3 | 2023 | 125 | 0.870 |
Why?
|
| Echocardiography, Three-Dimensional | 8 | 2020 | 528 | 0.860 |
Why?
|
| Humans | 89 | 2025 | 96105 | 0.850 |
Why?
|
| Stents | 5 | 2024 | 422 | 0.840 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 91 | 0.790 |
Why?
|
| Middle Aged | 37 | 2025 | 28368 | 0.780 |
Why?
|
| Hemodynamics | 6 | 2024 | 775 | 0.770 |
Why?
|
| Aged | 35 | 2025 | 20968 | 0.750 |
Why?
|
| Catheterization | 5 | 2017 | 238 | 0.750 |
Why?
|
| Pulmonary Embolism | 6 | 2021 | 235 | 0.740 |
Why?
|
| Atrial Appendage | 4 | 2024 | 39 | 0.730 |
Why?
|
| Registries | 7 | 2024 | 986 | 0.710 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 206 | 0.700 |
Why?
|
| Thrombolytic Therapy | 5 | 2021 | 261 | 0.690 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 334 | 0.680 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2019 | 72 | 0.680 |
Why?
|
| Retrospective Studies | 26 | 2025 | 10287 | 0.670 |
Why?
|
| Female | 50 | 2025 | 50028 | 0.670 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 392 | 0.650 |
Why?
|
| Electrocardiography | 6 | 2021 | 522 | 0.630 |
Why?
|
| Secondary Prevention | 1 | 2021 | 179 | 0.630 |
Why?
|
| Heart Diseases | 5 | 2021 | 314 | 0.630 |
Why?
|
| Coronary Artery Bypass | 4 | 2023 | 252 | 0.600 |
Why?
|
| Heart Ventricles | 4 | 2020 | 810 | 0.580 |
Why?
|
| Time Factors | 13 | 2025 | 5580 | 0.570 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.550 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 34 | 0.540 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 60 | 0.540 |
Why?
|
| Swine | 14 | 2016 | 598 | 0.540 |
Why?
|
| Clinical Protocols | 1 | 2018 | 162 | 0.530 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 43 | 0.530 |
Why?
|
| Balloon Occlusion | 3 | 2012 | 33 | 0.530 |
Why?
|
| Arteriovenous Fistula | 1 | 2018 | 54 | 0.530 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 125 | 0.520 |
Why?
|
| Blood Circulation | 1 | 2017 | 31 | 0.520 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 131 | 0.520 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.520 |
Why?
|
| Venae Cavae | 1 | 2017 | 12 | 0.520 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 166 | 0.520 |
Why?
|
| Device Removal | 1 | 2018 | 166 | 0.520 |
Why?
|
| Mitral Valve | 6 | 2020 | 279 | 0.520 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 24 | 0.520 |
Why?
|
| Aminophylline | 1 | 2016 | 14 | 0.510 |
Why?
|
| Bradycardia | 1 | 2016 | 45 | 0.500 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 32 | 0.500 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 240 | 0.500 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 219 | 0.490 |
Why?
|
| Dyspnea | 1 | 2016 | 87 | 0.480 |
Why?
|
| Stroke | 3 | 2024 | 1087 | 0.480 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 286 | 0.480 |
Why?
|
| Balloon Valvuloplasty | 1 | 2015 | 8 | 0.480 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.480 |
Why?
|
| Vascular Fistula | 1 | 2015 | 12 | 0.470 |
Why?
|
| Disease Management | 1 | 2018 | 360 | 0.470 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 156 | 0.450 |
Why?
|
| Fontan Procedure | 1 | 2015 | 56 | 0.450 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2020 | 209 | 0.450 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 118 | 0.450 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2591 | 0.450 |
Why?
|
| Ventricular Septum | 1 | 2014 | 16 | 0.440 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 167 | 0.440 |
Why?
|
| Heart Injuries | 1 | 2014 | 22 | 0.430 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 96 | 0.430 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 72 | 0.430 |
Why?
|
| Epinephrine | 2 | 2011 | 92 | 0.420 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 3927 | 0.420 |
Why?
|
| Aneurysm, False | 1 | 2014 | 55 | 0.410 |
Why?
|
| Adenosine | 1 | 2016 | 278 | 0.410 |
Why?
|
| Risk Assessment | 10 | 2020 | 2480 | 0.400 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2015 | 107 | 0.400 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 98 | 0.380 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 279 | 0.380 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 7229 | 0.370 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 380 | 0.370 |
Why?
|
| Biomarkers | 4 | 2019 | 1930 | 0.360 |
Why?
|
| Vascular Patency | 3 | 2021 | 127 | 0.360 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 181 | 0.350 |
Why?
|
| Adult | 15 | 2025 | 28721 | 0.350 |
Why?
|
| Thymosin | 1 | 2011 | 6 | 0.350 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 16 | 0.340 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.340 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 61 | 0.330 |
Why?
|
| Electric Countershock | 2 | 2011 | 64 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2012 | 263 | 0.320 |
Why?
|
| Ventricular Pressure | 3 | 2021 | 48 | 0.320 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 1979 | 0.320 |
Why?
|
| Myocarditis | 1 | 2010 | 58 | 0.320 |
Why?
|
| Coronary Thrombosis | 2 | 2017 | 16 | 0.310 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 205 | 0.310 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 193 | 0.310 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2534 | 0.300 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 247 | 0.300 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 22 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 403 | 0.300 |
Why?
|
| After-Hours Care | 1 | 2008 | 8 | 0.290 |
Why?
|
| Heart Rate | 2 | 2010 | 518 | 0.290 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 1805 | 0.290 |
Why?
|
| Risk Factors | 10 | 2021 | 5961 | 0.280 |
Why?
|
| Medical Errors | 1 | 2008 | 119 | 0.270 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.270 |
Why?
|
| Fish Oils | 1 | 2007 | 15 | 0.270 |
Why?
|
| United States | 8 | 2024 | 7768 | 0.270 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2007 | 22 | 0.270 |
Why?
|
| Coronary Circulation | 3 | 2024 | 133 | 0.260 |
Why?
|
| Vasodilation | 1 | 2007 | 96 | 0.260 |
Why?
|
| Docosahexaenoic Acids | 1 | 2007 | 35 | 0.260 |
Why?
|
| Hypoxia | 1 | 2012 | 681 | 0.260 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 300 | 0.240 |
Why?
|
| Thrombectomy | 1 | 2008 | 220 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 231 | 0.230 |
Why?
|
| Artifacts | 1 | 2007 | 252 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 437 | 0.230 |
Why?
|
| Saphenous Vein | 3 | 2010 | 61 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 395 | 0.220 |
Why?
|
| Ultrasonography | 4 | 2015 | 744 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 341 | 0.220 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 62 | 0.220 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 92 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 491 | 0.210 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 91 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 501 | 0.210 |
Why?
|
| Stroke Volume | 5 | 2021 | 531 | 0.210 |
Why?
|
| Carotid Arteries | 1 | 2024 | 136 | 0.200 |
Why?
|
| Cysteine | 1 | 2024 | 146 | 0.200 |
Why?
|
| Heart Transplantation | 2 | 2023 | 812 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 123 | 0.190 |
Why?
|
| Clinical Competence | 1 | 2008 | 854 | 0.190 |
Why?
|
| Osteosarcoma | 1 | 2003 | 160 | 0.190 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 341 | 0.190 |
Why?
|
| Microcirculation | 2 | 2024 | 104 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1429 | 0.190 |
Why?
|
| Coronary Restenosis | 4 | 2017 | 12 | 0.180 |
Why?
|
| Ulnar Artery | 1 | 2022 | 6 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 713 | 0.180 |
Why?
|
| Survival Rate | 5 | 2019 | 1985 | 0.180 |
Why?
|
| Radial Artery | 1 | 2022 | 37 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2024 | 819 | 0.180 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 777 | 0.180 |
Why?
|
| Aorta | 2 | 2020 | 294 | 0.180 |
Why?
|
| Hospitals | 2 | 2021 | 329 | 0.180 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 319 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2024 | 938 | 0.170 |
Why?
|
| Heart Atria | 3 | 2016 | 290 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 2061 | 0.170 |
Why?
|
| Everolimus | 1 | 2021 | 36 | 0.170 |
Why?
|
| Echocardiography | 5 | 2020 | 1004 | 0.170 |
Why?
|
| Acute Disease | 3 | 2021 | 872 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 2 | 2019 | 106 | 0.170 |
Why?
|
| Transillumination | 1 | 2020 | 9 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2021 | 463 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 2777 | 0.160 |
Why?
|
| Limb Salvage | 1 | 2020 | 38 | 0.160 |
Why?
|
| Cardiology | 1 | 2021 | 130 | 0.160 |
Why?
|
| Prognosis | 5 | 2024 | 4028 | 0.160 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2010 | 100 | 0.160 |
Why?
|
| Reoperation | 2 | 2013 | 707 | 0.160 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 15 | 0.160 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 84 | 0.160 |
Why?
|
| Animals | 15 | 2016 | 28891 | 0.150 |
Why?
|
| Mobile Applications | 1 | 2021 | 79 | 0.150 |
Why?
|
| Health Equity | 1 | 2021 | 103 | 0.150 |
Why?
|
| Resuscitation | 2 | 2011 | 131 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 188 | 0.150 |
Why?
|
| Recovery of Function | 2 | 2018 | 348 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2019 | 138 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 257 | 0.150 |
Why?
|
| Heart | 3 | 2020 | 591 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 2880 | 0.140 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2018 | 25 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 157 | 0.140 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 54 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 231 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 69 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 281 | 0.130 |
Why?
|
| Recurrence | 2 | 2012 | 1218 | 0.130 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 477 | 0.130 |
Why?
|
| Blood Pressure | 3 | 2013 | 926 | 0.130 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 7 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 27 | 0.130 |
Why?
|
| Triage | 1 | 2018 | 132 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1010 | 0.130 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 10 | 0.130 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 14 | 0.130 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 34 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 287 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 152 | 0.130 |
Why?
|
| Echocardiography, Doppler | 1 | 2017 | 193 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 2016 | 43 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 186 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 983 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 594 | 0.120 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 90 | 0.120 |
Why?
|
| Cannula | 1 | 2016 | 57 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 128 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 623 | 0.120 |
Why?
|
| Subclavian Artery | 1 | 2015 | 42 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 340 | 0.110 |
Why?
|
| Length of Stay | 1 | 2019 | 833 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2018 | 4671 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2016 | 304 | 0.110 |
Why?
|
| Random Allocation | 4 | 2020 | 325 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 340 | 0.110 |
Why?
|
| Comorbidity | 2 | 2015 | 1011 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 75 | 0.110 |
Why?
|
| Aortography | 1 | 2014 | 67 | 0.100 |
Why?
|
| California | 3 | 2010 | 161 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 17 | 0.100 |
Why?
|
| Contrast Media | 1 | 2018 | 1096 | 0.100 |
Why?
|
| Kidney | 1 | 2018 | 1137 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3639 | 0.100 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 51 | 0.100 |
Why?
|
| Amiodarone | 1 | 2013 | 15 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 72 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1619 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 38 | 0.100 |
Why?
|
| Dobutamine | 1 | 2013 | 62 | 0.100 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 52 | 0.100 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 69 | 0.100 |
Why?
|
| Software | 1 | 2017 | 698 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 266 | 0.090 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 123 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 700 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2016 | 1546 | 0.090 |
Why?
|
| Algorithms | 2 | 2017 | 2015 | 0.090 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2012 | 7 | 0.090 |
Why?
|
| Exercise Test | 1 | 2013 | 178 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2014 | 307 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 258 | 0.090 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 38 | 0.090 |
Why?
|
| Labetalol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Metoprolol | 1 | 2011 | 15 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 154 | 0.090 |
Why?
|
| Vascular Resistance | 2 | 2024 | 104 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 110 | 0.080 |
Why?
|
| Catheters | 2 | 2021 | 90 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 155 | 0.080 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 28 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 935 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 481 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 249 | 0.080 |
Why?
|
| Creatine Kinase | 1 | 2010 | 53 | 0.080 |
Why?
|
| Vasopressins | 1 | 2010 | 50 | 0.080 |
Why?
|
| Infliximab | 4 | 2013 | 163 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 94 | 0.080 |
Why?
|
| Troponin | 1 | 2010 | 28 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 273 | 0.080 |
Why?
|
| Proteinuria | 1 | 2010 | 69 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 114 | 0.080 |
Why?
|
| Patient Selection | 3 | 2020 | 709 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2010 | 108 | 0.080 |
Why?
|
| Coronary Sinus | 1 | 2010 | 10 | 0.080 |
Why?
|
| Myocardium | 2 | 2010 | 592 | 0.080 |
Why?
|
| Critical Illness | 1 | 2012 | 346 | 0.080 |
Why?
|
| Sirolimus | 1 | 2010 | 177 | 0.070 |
Why?
|
| Endothelin-2 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2010 | 397 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2039 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2010 | 497 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 148 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2011 | 740 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 381 | 0.070 |
Why?
|
| Chicago | 1 | 2013 | 1506 | 0.070 |
Why?
|
| Diastole | 2 | 2018 | 147 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 185 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 133 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 2007 | 24 | 0.070 |
Why?
|
| Vitamin E | 1 | 2007 | 34 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 102 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 36 | 0.070 |
Why?
|
| Selection Bias | 1 | 2007 | 38 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2007 | 162 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 816 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2007 | 214 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 245 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 153 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2007 | 133 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 169 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 31 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Observer Variation | 1 | 2007 | 626 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 871 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 995 | 0.060 |
Why?
|
| Metals | 1 | 2005 | 102 | 0.060 |
Why?
|
| Action Potentials | 1 | 2008 | 618 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1667 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 569 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 682 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 156 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 297 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 239 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 7025 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 243 | 0.050 |
Why?
|
| Spasm | 1 | 2022 | 19 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2015 | 418 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1957 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 98 | 0.040 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2020 | 159 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 542 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 363 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 379 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1349 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 294 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 28 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 713 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 483 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 901 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 481 | 0.030 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 112 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 427 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 79 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1756 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 358 | 0.030 |
Why?
|
| Phlebography | 1 | 2017 | 67 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 531 | 0.030 |
Why?
|
| Oxygen | 1 | 2021 | 781 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1816 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 491 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 386 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 295 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 296 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 458 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 323 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 565 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2013 | 6 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 21 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 33 | 0.020 |
Why?
|
| Lidocaine | 1 | 2013 | 67 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 2013 | 30 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 196 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 90 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 162 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 151 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 674 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 48 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 220 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 311 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 647 | 0.020 |
Why?
|
| Adolescent | 1 | 2003 | 9895 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 89 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 299 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 161 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2008 | 7 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1963 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 286 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 883 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 1196 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 228 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1133 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2006 | 55 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 271 | 0.010 |
Why?
|
| Collagen | 1 | 2006 | 306 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 25 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 908 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 32 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2003 | 61 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 149 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 472 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 639 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1715 | 0.010 |
Why?
|